Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The potential oncology collaboration..

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Nov 04, 2022 6:45pm

94 Views

Post# 35074703

RE:RE:RE:RE:The potential oncology collaboration..

I would've expected JNCE's stock to skyrocket on the news of their recent partnership. The stock continued to drop. Does that concern anyone for our next potential moves with THTX?

PWIB123 wrote: I believe Jounce Therapeutics (JNCE) was used as an example of a deal that would be celebrated. Does it worry anybody that there was no big stock price jump on the news of that deal? Quite the opposite, the stock is continuing to drop.

scarlet1967 wrote: I believe the trial designs can be modified to serve the purpose for instance multi-center clinical trials with diverse ethnicity so the data can be presented to various related/targeted regional authorities, for instance THTX could start collaborating with a Chinese partner running trials in China the results from those centers and other centers can be presented to Chinese and other relevant authorities outside China or they can of course let the Chinese run their own trials. Thats my undrestanding, possibly a bit more complex and then add the politics to the mix!!

Wino115 wrote: Should have listed on HKSE instead of NASDAQ. We'd have $3bil mkt cap by now. ;-)
I think a deal will come fairly quickly on the back of just announcing they will be filing at least one pivotal for a specific cancer. They can then get full value on that with a partner and the partner can get first look at anything else, knowing full well they'll have to pay "market" at that time on whatever that indication is. I am not totally familiar with Chineses "FDA-like" approval processes but I would think it's like most countries where trials are for specific uses only and based solely on trial data (perhaps globally but I don't know).

scarlet1967 wrote:
Is for China only as per the company, there isn't many articles duplicated or not about their research anywhere yet these posts keep popping up from China.

https://www.pharmadeer.com/blognews/post/43668.html